Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the ...

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

You have been exercising, eating home-cooked meals, and have managed to cut out fried food and desserts from your diet for ...

The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

The B.C. government is restricting the sales of two more diabetes drugs to people outside Canada amid rising demand for the ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

Morgans healthcare and life sciences expert Iain Wilkie explains what the movers and shakers have been doing in health and ...